Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound preparation for treating relevant vascular diseases and preparation method thereof

The technology of compound preparation and compound tablet, which is applied in the field of medicine, can solve the problems of inability to effectively improve the symptoms of intermittent claudication in patients with peripheral arterial occlusion, and achieve the effects of significant vascular-related diseases, simple production process and long shelf life.

Active Publication Date: 2010-11-10
XIAN LIBANG PHARMA
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Mohler et al. found that beraprost sodium could not effectively improve the symptoms of intermittent claudication in patients with peripheral artery occlusion under the condition that the selection criteria, test methods, and observation indicators were similar to those of the former.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation for treating relevant vascular diseases and preparation method thereof
  • Compound preparation for treating relevant vascular diseases and preparation method thereof
  • Compound preparation for treating relevant vascular diseases and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] The preparation of embodiment 1 compound tablet

[0076] formula:

[0077]

[0078]

[0079] Preparation:

[0080] (1) Mix the prescribed amount of beraprost sodium, cilostazol, cross-linked polyvinylpyrrolidone, and sodium lauryl sulfate evenly, and grind in a grinder to obtain a solid dispersion powder with a particle size of 50 μm or less ;

[0081] (2) Add the prescribed amount of starch, make a soft material with 5% polyvinylpyrrolidone and 50% ethanol aqueous solution, pass through a 20-mesh sieve, and ventilate and dry at 35°C;

[0082] (3) After drying, add the prescribed amount of magnesium stearate, mix evenly, granulate, compress into tablets, and obtain compound tablets.

Embodiment 2

[0083] The preparation of embodiment 2 slow-release compound tablet

[0084] formula:

[0085]

[0086] Preparation:

[0087] (1) After mixing evenly the beraprost sodium and cilostazol of the prescribed amount with cross-linked polyvinylpyrrolidone, sodium lauryl sulfate and sodium hydroxypropyl cellulose, they are placed in a grinder and ground to obtain a particle size It is a solid dispersed powder below 50 μm;

[0088] (2) Add the prescribed amount of starch, make a soft material with 5% polyvinylpyrrolidone and 50% ethanol aqueous solution, pass through a 20-mesh sieve, and ventilate and dry at 35°C;

[0089] (3) After drying, add the prescribed amount of magnesium stearate, mix evenly, granulate, compress into tablets, and obtain compound tablets.

Embodiment 3

[0090] The preparation of embodiment 3 compound capsules

[0091] formula:

[0092]

[0093] Preparation:

[0094] Take the prescribed amount of beraprost sodium and cilostazol and gradually dilute them with the prescribed amount of starch in equal increments, add the prescribed amount of antioxidant vitamin C and mix evenly, add an appropriate amount of 10% starch slurry, granulate, dry, Whole grains, and then choose moisture-proof and anti-oxidation coating powder to coat it, dry, sieve, and pack into capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of pharmacy, and in particular relates to a compound preparation for treating relevant vascular diseases. The compound preparation consists of the following two active ingredients: beraprost or a pharmaceutically-acceptable salt thereof and cilostazol or a pharmaceutically-acceptable salt thereof, wherein the weight ratio of the beraprost or the pharmaceutically-acceptable salt thereof to the cilostazol or the pharmaceutically-acceptable salt thereof is 0.5-2: 750-3,000.

Description

technical field [0001] The invention belongs to the technical field of medicine, and mainly relates to a compound preparation for treating blood vessel-related diseases and a preparation method thereof. Background technique [0002] Lower extremity arteriosclerosis obliterans (ASO) is one of the common diseases of the elderly. In people over the age of 50 with diabetes or smokers, the incidence of ASO is as high as 29%. The clinical symptoms of ASO are coldness, numbness and intermittent claudication of the affected limb in the early stage, gangrene may occur in the middle and late stages, and severe cases may lead to infection, amputation, or even death. Therefore, how to effectively prevent and treat ASO and reduce arterial restenosis after ASO surgery or interventional therapy has attracted increasing attention. [0003] Prostacyclin (PGI2) is a vasoactive substance synthesized by vascular endothelial cells. It activates adenylyl cyclase through the PGI2 receptor of pla...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5585A61K31/4709A61P9/00A61P7/02A61P9/08A61P9/10
Inventor 王汝涛陈涛胡惠静王惟娇张阳
Owner XIAN LIBANG PHARMA
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com